Harvard Bioscience (HBIO) Rejects Skystone Buyout Offer

December 17, 2007 7:30 AM EST

Harvard Bioscience (Nasdaq: HBIO) today announced that its Board of Directors unanimously rejected an unsolicited buyout offer from Skystone Advisors LLC to acquire all outstanding shares of the Company's common stock for $5.00 per share.

Harvard Bioscience, Inc. develops, distributes, manufactures, and markets apparatus and scientific instruments used in life science research at pharmaceutical and biotechnology companies, universities, and government laboratories worldwide.

Create E-mail AlertRelated Categories

Corporate News
Mergers and Acquisitions

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?